Cyclo rgdfk

Anti-Src (clone 2108), anti-pSrc at tyr416 (clone 2101), anti-FAK (clone 3285) and anti-pFAK at tyr397 (clone 3283) were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-Fyn (clone MA1-19331) and anti-pFyn at tyr530 (clone PA5-38115) were purchased from Thermo Fisher (Waltham, MA, USA). Anti-HA (clone H6908) was purchased form Sigma-Aldrich (St. Louis, MO, USA). Anti-Kv2.1 (clone K89/34) was purchased from NeuroMab (University of California Davis), UC Davis (Davis, CA, USA)/NIH (Bethesda, MA, USA). Anti-Integrin-α5 (clone sc-10729) and goat anti-rabbit IgG-R (clone sc-2091) were purchased from Santa Cruz biotechnology (Dallas, TX, USA). Cyclo (-RGDfK) dissolved in water (100 mM) and PND-1186 dissolved in dimethyl sulfoxide (DMSO) (100 mM) were purchased from APExBIO (Houston, TX, USA).

MCF7, MDA-MB-231, and SUM-159 cells were cultured in Dulbecco’s Modified Eagle’s Medium (Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 mg/mL streptomycin. All cell lines were cultured in a humidified atmosphere of 5% CO₂ at 37 °C. For treatments with the following inhibitors, cells were seeded at the same density and allowed to adhere for 24 h under normal conditions before treatment with the indicated concentrations of different inhibitors. The inhibitors including AZD8330 (A8374), SB203580 (A8254), SP600125 (A4604), PS-1145 (B6089), (5Z)-7-Oxozeaenol (B7443), MK2206 (A3010), LY2109761 (A8464), and Cyclo-RGDfK (A8164) were purchased from APExBIO (Houston, TX, USA). Belvarafenib (S8853) was purchased from Selleck Chemicals (Houston, TX, USA), and UK122 (sc-356185) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).